Arbutus Biopharma Corporation
HealthcareNASDAQ:ABUS · NASDAQ Global Select
-$0.03 today
Vol 0.94M · Avg 1.78M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-43.7%
avg -75.4%
ROIC
-30.3%
avg -59.3%
ROA
-35.4%
avg -55.7%
Analysis
ROIC is currently the strongest return metric at -30.3% versus its period average of -59.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Lindsay Androski | President, Chief Executive Officer & Chairman | $736,559.00 | — | 49 | $71,700.00 | 0.04% |
Tuan Nguyen | Chief Financial Officer | $651,897.00 | — | 50 | $73,500.00 | 0.04% |
Andrew J. Sung | General Counsel | — | — | — | $220,300.00 | 0.11% |
R. Hector Mackay-Dunn | Corporate Secretary | — | — | 75 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +20.6% | +14.9% (14yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +20.6% over three years. Forward estimates point to Revenue at +14.9% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
Nanobiotix S.A.
NASDAQ:NBTX
$1.80B
Septerna, Inc.
NASDAQ:SEPN
$1.62B
GH Research PLC
NASDAQ:GHRS
$1.45B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.19B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Savara Inc.
NASDAQ:SVRA
$1.08B
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
$969.20M
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
ProKidney Corp.
NASDAQ:PROK
$242.99M
Who manages ABUS?
Arbutus Biopharma Corporation (ABUS) lists 4 active executives. The top listed executive is Andrew J. Sung, General Counsel.
Are ABUS insiders buying or selling?
Recent insider activity shows net buying of $73.37M.
Explore More
Continue the stock analysis
Jump to another research area for this company.